IN2015DN02573A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02573A
IN2015DN02573A IN2573DEN2015A IN2015DN02573A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A IN 2573DEN2015 A IN2573DEN2015 A IN 2573DEN2015A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A
Authority
IN
India
Prior art keywords
pulmonary fibrosis
compound
present
formula
idiopathic
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf; Nilsson
Hakon; Leffler
Neil; Henderson
Tariq; Sethi
Alison; Mackinnon
Original Assignee
Galecto Biotech Ab
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech Ab, Univ Edinburgh filed Critical Galecto Biotech Ab
Publication of IN2015DN02573A publication Critical patent/IN2015DN02573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN2573DEN2015 2012-10-31 2013-10-30 IN2015DN02573A (enEXAMPLES)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
IN2015DN02573A true IN2015DN02573A (enEXAMPLES) 2015-09-11

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2573DEN2015 IN2015DN02573A (enEXAMPLES) 2012-10-31 2013-10-30

Country Status (7)

Country Link
EP (2) EP2914269B1 (enEXAMPLES)
JP (1) JP2015535233A (enEXAMPLES)
CN (1) CN104755088A (enEXAMPLES)
CA (1) CA2884802A1 (enEXAMPLES)
ES (1) ES2817888T3 (enEXAMPLES)
IN (1) IN2015DN02573A (enEXAMPLES)
WO (1) WO2014067986A1 (enEXAMPLES)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
US10464964B2 (en) 2015-01-16 2019-11-05 Galecto Biotech Ab Galactoside inhibitor of galectins
CN107406478B (zh) 2015-01-30 2021-07-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CA2983198C (en) 2015-05-12 2022-07-19 Galecto Biotech Ab Once-daily treatment of pulmonary fibrosis
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
WO2017080973A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab 1,1 '-sulfanediyl-di-beta-d-galactopyranosides as inhibitors of galectins
EP3896075A1 (en) 2015-12-18 2021-10-20 Galecto Biotech AB Polymorphic forms and process
EP3423461A4 (en) * 2016-03-04 2020-03-25 Galectin Sciences, LLC SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THEIR USE
WO2018011093A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US10889610B2 (en) 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
BR112019023722A2 (pt) * 2017-05-12 2020-05-26 Galectin Sciences, Llc Compostos para a prevenção e tratamento de doenças e o uso dos mesmos
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EP3737686A1 (en) 2018-01-10 2020-11-18 Galecto Biotech AB Novel galactoside inhibitor of galectins
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
KR102802503B1 (ko) 2018-06-15 2025-04-29 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제로서의 테트라히드로피란-기재 티오디사카라이드 모방체
WO2020002765A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2020117883A1 (en) 2018-12-06 2020-06-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
AU2019416330A1 (en) 2018-12-27 2021-07-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7478165B2 (ja) 2019-03-26 2024-05-02 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
JP7577682B2 (ja) 2019-04-10 2024-11-05 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
EP3983423A4 (en) * 2019-06-14 2023-07-19 Université Laval Synthesis of 3-azido-3-deoxy-d-galactopyranose
JP2022537737A (ja) * 2019-06-24 2022-08-29 ガレクト バイオテック エービー ３，３’－ジデオキシ－３，３’－ビス－［４－（３－フルオロフェニル）－１ｈ－１，２，３－トリアゾル－１－イル］－１，１’－スルファンジイル－ジ－ベータ－ｄ－ガラクトピラノシドの大規模方法
CA3141436A1 (en) 2019-07-03 2021-01-07 Fredrik Zetterberg Novel galactoside inhibitor of galectins
WO2021001538A1 (en) 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
WO2021004940A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
KR102854071B1 (ko) 2019-08-09 2025-09-02 이도르시아 파마슈티컬스 리미티드 (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체
JP7612663B2 (ja) 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体
WO2021028570A1 (en) 2019-08-15 2021-02-18 Idorsia Pharmaceuticals Ltd 2-hydroxycycloalkane-1-carbamoyl derivatives
PL4021904T3 (pl) 2019-08-29 2024-05-13 Idorsia Pharmaceuticals Ltd Pochodne alfa-d-galaktopiranozydu
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
WO2021195020A1 (en) * 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
CN115362160A (zh) * 2020-03-31 2022-11-18 格莱克特生物技术公司 用于制备1,2,4,6-四-o-乙酰基-3-叠氮基-3-脱氧-d-吡喃半乳糖苷的大规模方法
US12275720B2 (en) 2020-05-05 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12286424B2 (en) 2020-05-11 2025-04-29 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2021242982A1 (en) 2020-05-28 2021-12-02 Bristol-Myers Squibb Company Galectin-3 inhibitors
AU2021356076A1 (en) 2020-10-06 2023-06-08 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
WO2022171594A1 (en) 2021-02-09 2022-08-18 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
CA3209917A1 (en) 2021-03-03 2022-09-09 Martin Bolli Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
WO2025111704A1 (en) * 2023-12-01 2025-06-05 UNIVERSITé LAVAL Selective inhibitors of galectin-3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3470380D1 (en) 1984-08-09 1988-05-19 Inge Brugger Nebulizer
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
CA2444415A1 (en) 1991-07-02 1993-01-21 Nektar Therapeutics Method and device for delivering aerosolized medicaments
DE69618624T2 (de) 1996-01-03 2002-08-08 Glaxo Group Ltd., Greenford Inhaliervorrichtung
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
DE50102690D1 (de) 2001-10-18 2004-07-29 Pari Gmbh Inhalationstherapievorrichtung
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
WO2006009209A1 (ja) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. 慢性炎症性肺疾患を予防もしくは治療する薬剤
CN102439021B (zh) 2009-04-28 2015-09-02 格莱克特生物技术公司 半乳凝素的新型半乳糖苷抑制剂
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
MX359516B (es) * 2011-04-12 2018-10-01 Moerae Matrix Inc Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.

Also Published As

Publication number Publication date
EP2914269B1 (en) 2020-07-29
ES2817888T3 (es) 2021-04-08
WO2014067986A8 (en) 2016-04-14
EP2914269A1 (en) 2015-09-09
EP3278805A1 (en) 2018-02-07
WO2014067986A1 (en) 2014-05-08
JP2015535233A (ja) 2015-12-10
CA2884802A1 (en) 2014-05-08
CN104755088A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
IN2015DN02573A (enEXAMPLES)
NZ708501A (en) Treatment of pulmonary disease
IN2015DN01156A (enEXAMPLES)
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
TN2014000095A1 (en) Pharmaceutical compositions
MX2015007916A (es) Peri-carbinoles.
MX2015008187A (es) Inhibidores de alk deuterados.
PH12014500990A1 (en) Methods for treating gout flares
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX347541B (es) Analogos de acido sialico.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12014502065A1 (en) Vesicular formulations
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
TN2013000023A1 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases